Symberix is a preclinical-stage biotech developing first-in-class symbiotic drugs that improve cancer and gastrointestinal treatment outcomes by precisely controlling bacteria within the human microbiome.
Pioneering the human gusome with science-driven precision microbiome medicine.
Symberix, an early-stage spin-out of the University of North Carolina at Chapel Hill, aims to improve human health by pioneering the development of symbiotic drugs that work by controlling bacteria without killing them. Symberix’s scientific founder, Matthew Redinbo, PhD, was the first to demonstrate the feasibility of therapeutically controlling the mammalian microbiome with small-molecule symbiotic drugs. Based on this breakthrough research, the company is advancing a first-in-class approach to improve the treatment of serious lower gastrointestinal (GI) diseases as well as mitigate the debilitating lower GI side effects associated with various cancer, pain and immunosuppressive therapies. Our vision: Safe and effective pharmaceutical control of the microbiome.
Advancing first-in-class drug candidates for chemotherapy toxicity, colorectal cancer, IBD, and other intestinal indications.
Symberix in the press — awards, publications, and announcements.
Symberix joins the Blackstone Entrepreneurs Network portfolio — gaining mentorship and strategic support for microbiome drug development.
Read more →Symberix selected as a featured showcase presenter at the CED Life Science Conference, highlighting our first-in-class microbiome inhibitor pipeline.
Read more →Genetic Engineering News highlights Symberix in a feature article on microbiome-targeted therapeutics and bacterial enzyme inhibitors.
Read more →Interested in our science, pipeline, or career opportunities? We’d love to hear from you.
Get in touch